This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The usefulness of genotype resistance testing in the clinical management of HIV infection is increasingly clear. However, as Dr Hirsch and colleagues¹ state, several technical issues concerning standardization and clinical validation have yet to be resolved.

Although genotypic assays are increasingly common in the clinical setting, interpretation of results is more complex than merely identifying mutations and then eliminating antiretroviral drugs that supposedly are not efficacious. In fact, the same combinations of primary and secondary mutations may result from several different scenarios.

Genotypic testing shows the mutational pattern detected in the amplicon. This does not necessarily correspond to a single viral clone because the same pattern may result from the superimposition of the genotypes from different clones. It may be quite misleading to assume that all mutations belong to the same clone, as is often done in a more conservative therapeutical approach. On the other hand, given . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: Recommendations of an International AIDS Society–USA Panel
Martin S. Hirsch, Françoise Brun-Vézinet, Richard T. D'Aquila, Scott M. Hammer, Victoria A. Johnson, Daniel R. Kuritzkes, Clive Loveday, John W. Mellors, Bonaventura Clotet, Brian Conway, Lisa M. Demeter, Stefano Vella, Donna M. Jacobsen, and Douglas D. Richman
JAMA. 2000;283(18):2417-2426.
ABSTRACT | FULL TEXT  

Antiretroviral Drug Resistance Testing in Adults With HIV Infection: Implications for Clinical Management
Martin S. Hirsch, Brian Conway, Richard T. D'Aquila, Victoria A. Johnson, Françoise Brun-Vézinet, Bonaventura Clotet, Lisa M. Demeter, Scott M. Hammer, Donna M. Jacobsen, Daniel R. Kuritzkes, Clive Loveday, John W. Mellors, Stefano Vella, Douglas D. Richman, and for the International AIDS Society–USA Panel
JAMA. 1998;279(24):1984-1991.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Interruption of Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) Therapy for 2 Months Has No Effect on Levels of Human Immunodeficiency Virus Type 1 in Plasma of Patients Harboring Viruses with Mutations Associated with Resistance to NNRTIs
Wirden et al.
J. Clin. Microbiol. 2003;41:2713-2715.
ABSTRACT | FULL TEXT  

P-Glycoprotein Expression by Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus-Infected Patients Is Independent from Response to Highly Active Antiretroviral Therapy
Agrati et al.
CVI 2003;10:191-192.
FULL TEXT  

Testing Genotypic and Phenotypic Resistance in Human Immunodeficiency Virus Type 1 Isolates of Clade B and Other Clades from Children Failing Antiretroviral Therapy
Brindeiro et al.
J. Clin. Microbiol. 2002;40:4512-4519.
ABSTRACT | FULL TEXT